A scheme for defining cause of death and its application in the T cell depletion trial

被引:134
作者
Copelan, Edward
Casper, James T.
Carter, Shelly L.
van Burik, Jo-Anne H.
Hurd, David
Mendizabal, Adam M.
Wagner, John E.
Yanovich, Saul
Kernan, Nancy A.
机构
[1] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] EMMES Corp, Rockville, MD USA
[4] Univ Minnesota, Minneapolis, MN USA
[5] Wake Forest Univ, Winston Salem, NC 27109 USA
[6] Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
cause of death; hematopoietic stem cell transplantation; T cell depletion;
D O I
10.1016/j.bbmt.2007.08.047
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The primary cause of death (COD) provides important information in many studies of hematopoietic stem cell transplantation (HSCT). A panel of experts critically assessed the CODs submitted by 15 transplantation centers for 281 patients who died in a randomized multicenter trial of unrelated HSCT. The panel reviewed the CODs reported by the transplantation centers, which used the Center for International Blood and Marrow Transplant Research and National Marrow Donor Program COD reporting form. The panel determined that the existing criteria for primary and contributing CODs lacked sufficient stringency for uniform interpretation. A hierarchy was developed and applied to the T cell depletion project. Using its scheme, the panel reclassified 157 CODs (56%) reported by the transplantation centers. The changes resulted in increased recognition of graft-versus-host disease as the primary COD and a concomitant decrease in attribution of the primary COD to infection. This algorithm promotes consistent assignment of primary and contributing CODs for patients with leukemia or lymphoma who expire after myeloablative allogeneic HSCT. (c) 2007 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:1469 / 1476
页数:8
相关论文
共 10 条
[1]
REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[2]
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy [J].
Cohen, MH ;
French, AL ;
Benning, L ;
Kovacs, A ;
Anastos, K ;
Young, M ;
Minkoff, H ;
Hessol, NA .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (02) :91-98
[3]
Umbilical Cord Blood Transplantation in adults: Results of the prospective Cord Blood Transplantation (COBLT) [J].
Cornetta, K ;
Laughlin, M ;
Carter, S ;
Wall, D ;
Weinthal, J ;
Delaney, C ;
Wagner, J ;
Sweetman, R ;
McCarthy, P ;
Chao, N .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) :149-160
[4]
Clinical utility of autopsy after hematopoietic stem cell transplantation [J].
Hofmeister, Craig C. ;
Marinier, David E. ;
Czerlanis, Cheryl ;
Stiff, Patrick J. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) :26-30
[5]
Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation [J].
Pavletic, SZ ;
Carter, SL ;
Kernan, NA ;
Henslee-Downey, J ;
Mendizabal, AM ;
Papadopoulos, E ;
Gingrich, R ;
Casper, J ;
Yanovich, S ;
Weisdorf, D .
BLOOD, 2005, 106 (09) :3308-3313
[6]
Management of cytomegalovirus in the pediatric bone marrow/stem cell transplantation population [J].
Stanton, TJ ;
Martin, PL ;
Talbert, G .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) :104-104
[7]
The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis - An autopsy study of 355 patients [J].
van Burik, JAH ;
Leisenring, W ;
Myerson, D ;
Hackman, RC ;
Shulman, HM ;
Sale, GE ;
Bowden, RA ;
McDonald, GB .
MEDICINE, 1998, 77 (04) :246-254
[8]
Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial [J].
Wagner, JE ;
Thompson, JS ;
Carter, SL ;
Kernan, NA .
LANCET, 2005, 366 (9487) :733-741
[9]
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: The cord blood transplantation study (COBLT) experience [J].
Wall, DA ;
Carter, SL ;
Kernan, NA ;
Kapoor, N ;
Kamani, NR ;
Brochstein, JA ;
Frangoul, H ;
Goyal, RK ;
Horan, JT ;
Pietryga, D ;
Wagner, JE ;
Kurtzberg, J .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (08) :637-646
[10]
Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review [J].
Weisdorf, DJ ;
Hurd, D ;
Carter, S ;
Howe, C ;
Jensen, LA ;
Wagner, J ;
Stablein, D ;
Thompson, J ;
Kernan, NA .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (08) :512-518